One possible reason that Connaught

One possible reason that Connaught temporarily discontinued patenting
is its potential entrance in the U.S. market, over which Merieux had a stronghold. In this light Merieux may have viewed any enrichment of
Connaught’s business as tantamount to enriching a potential competitor in
the same market. Even though the consent decree was flexible enough to
enable Merieux to recoup any improvements it made to the Connaught
business, given that the decree called for a reasonable lump sum payment
by the licensee, Merieux’s competitive interests arguably created an incentive
to neglect Connaught’s rabies vaccine business while enriching its
own. Indeed, during the same period in which Connaught did not file for
any patents, Merieux sustained its lead in the rabies vaccine business, filing
for a patent in late 1991, and launching a new product, Raboral, in
1992.

Hasil (Bahasa Indonesia) 1:

Satu kemungkinan alasan bahwa Connaught sementara dihentikan patenadalah pintu masuk yang potensial di pasar AS, yang Merieux telah kubu. Merieux cahaya ini mungkin telah melihat apapun pengayaanBisnis Connaught sebagai sama memperkaya pesaing yang potensial dipasar yang sama. Meskipun keputusan izin cukup fleksibel untukmengaktifkan Merieux untuk menutup perbaikan dibuat untuk ConnaughtBisnis, diberi keputusan menyerukan wajar lumsum pembayarandengan lisensi, kepentingan kompetitif Merieux's diperdebatkan menciptakan insentifuntuk mengabaikan Connaught rabies vaksin bisnis sementara memperkaya nyasendiri. Memang, selama periode yang sama di mana Connaught tidak mengajukan untuksetiap paten, Merieux berkelanjutan yang memimpin dalam bisnis vaksin rabies, pengajuanuntuk paten di akhir 1991, dan meluncurkan produk baru, Raboral, di1992.